Failure of Novartis’ Pelacarsen Could Reshape the Lp(a) Race for CRISPR and Ionis
Novartis' Phase 3 trial for Pelacarsen showed it lowered lipoprotein(a) but failed to reduce major cardiovascular events. Citi suggests this may influence CRISPR Therapeutics' focus on CTX321 over CTX320, while Ionis Pharmaceuticals may see limited impact. Citi maintains Buy ratings for both companies with price targets of $88 for CRISPR and $100 for Ionis.
How this was made
The 30-second read
Why it matters
The news reshapes expectations for Lp(a) therapeutics and may redirect R&D focus.
Market read
Phase 3 trial outcome is a primary disclosure affecting three listed biotech stocks.
What to watch
Long‑term data on safety and regulatory pathways may outweigh short‑term efficacy concerns.
Background
Novartis' pelacarsen trial failure and analyst commentary on CRISPR Therapeutics and Ionis.
Ticker impact
Novartis' Phase 3 HORIZON trial of pelacarsen failed to show a significant reduction in major cardiovascular events.
Potential short-term downside as investors reassess Lp(a) strategy.
Phase 3 failure is a material clinical setback for a large pharma.
Citi suggests the pelacarsen failure could shift CRISPR Therapeutics' focus to its next‑gen Lp(a) candidate CTX321.
Possible upside on news of increased focus on CTX321.
Shift in pipeline priority is a forward‑looking catalyst.
Ionis is expected to see limited downside from the HORIZON result, with no impact on its FY2026 guidance.
Minimal price movement expected.
Guidance unchanged and market expectations already modest.
Market effects
The result may temper enthusiasm for Lp(a) lowering therapies across biotech.
European biotech stocks could see modest pressure.
Highlights challenges in cardiovascular gene‑editing approaches.
Counterpoint
The setback could open valuation gaps for competitors with alternative mechanisms.
Key entities
- companyNovartis AG
Swiss pharmaceutical company conducting the pelacarsen trial.
- companyCRISPR Therapeutics
Biotech developing CTX321 and CTX320 Lp(a) programs.
- companyIonis Pharmaceuticals
Original developer of pelacarsen.
